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ABSTRACT 
BACKGROUND: Surrogate endpoints in rectal cancer after preoperative chemoradiation are 
lacking as their statistical validation poses major challenges, including confirmation based on 
large phase 3 trials. We examined the prognostic role and individual-level surrogacy of 
neoadjuvant rectal (NAR) score that incorporates weighted cT, ypT and ypN categories for 
disease-free survival (DFS) in 1191 patients with rectal carcinoma treated within the 
CAO/ARO/AIO-04 phase 3 trial. 
PATIENTS AND METHODS: Cox regression models adjusted for treatment arm, resection 
status, and NAR score were used in multivariable analysis. The four Prentice criteria (PC1-4) 
were used to assess individual-level surrogacy of NAR for DFS.  
RESULTS: After a median follow-up of 50 months, the addition of oxaliplatin to 
fluorouracil-based chemoradiotherapy (CRT) significantly improved 3-year DFS (75.9% 
[95% CI 72.30-79.50] vs 71.3% [95% CI 67.60-74.90]; P=0.034; PC 1) and resulted in a shift 
towards lower NAR groups (P=0.034, PC 2) compared to fluorouracil-only CRT. The 3-year 
DFS was 91.7% (95% CI, 88.2 95.2), 81.8% (95% CI, 78.4-85.1) and 58.1 (95% CI 52.4-
63.9) for low, intermediate and high NAR score, respectively (P<0.001; PC 3). NAR score 
remained an independent prognostic factor for DFS (low vs high NAR: HR 4.670; 95% CI 
3.106-7.020; P<0.001; low vs intermediate NAR: HR 1.971; 95% CI 1.303-2.98; P=0.001) in 
multivariable analysis. Notwithstanding the inherent methodological difficulty in 
interpretation of PC 4 to establish surrogacy, the treatment effect on DFS was captured by 
NAR, supporting satisfaction of individual-level PC4.  
CONCLUSION: Our study validates the prognostic role and individual-level surrogacy of 
NAR score for DFS within a large randomized phase 3 trial. NAR score could help 
oncologists to speed up response-adapted therapeutic decision, and further large phase 3 trial 
datasets should aim to confirm trial-level surrogacy. 
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KEY MESSAGE 
In this secondary analysis in 1191 patients treated within the CAO/ARO/AIO-04 phase 3 
trial, the neoadjuvant rectal (NAR) cancer score was a prognostic factor and individual-level 
surrogate endpoint for disease-free survival in rectal cancer. NAR score can predict treatment 
effects on the clinical outcome and could help oncologists to speed up response-adapted 
therapeutic decisions. 
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INTRODUCTION 
Following the implementation of preoperative treatment, it has become apparent that rectal 
cancer response to chemoradiotherapy (CRT) varies considerably, ranging from complete 
tumor disappearance to lack of response, or even disease progression [1]. Early variables to 
assess tumor response, such as downsizing, downstaging, and tumor regression grading 
(TRG), have been proposed to reflect tumor biology, treatment efficacy and patients’ 
prognosis [2, 3], and may be used as surrogates for disease-free (DFS) and overall survival 
(OS).  
The interest in early surrogate endpoints has grown considerably in oncology trials [4, 5]. 
Surrogate endpoints are early indirect measures of true clinical endpoints and can decrease 
the number of patients and time needed to complete a trial, enabling early and less costly 
assessment of the benefit of experimental treatments [6]. The establishment of surrogate 
markers poses a challenge as it requires rigorous statistical validation using large trial 
datasets. Also, whether surrogate endpoints reflect true clinical benefit is discussed 
controversially [4, 5]. In that context, the neoadjuvant rectal (NAR) score has been recently 
proposed by the National Surgical Adjuvant Breast and Bowel Project (NSABP), the 
Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG) 
(NRG) Oncology to serve as a potential surrogate for clinical endpoints in trials testing 
preoperative treatment in rectal cancer The NAR score was developed on the basis of 
Valentini’s nomograms for OS [7] incorporating a weighted combination of the pre-CRT cT-
category, and post-CRT ypT- and ypN-categories and represents a pseudo-continuous 
variable with 24 possible discrete scores, ranging from 0–100 [8]. In the NSABP R-04 trial, 
the NAR score was classified as low (NAR<8), intermediate (NAR=8-16), and high 
(NAR>16) according to the tertiles of the observed scores, and lower NAR score was 
associated with better OS [8].  
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We investigated the prognostic value of NAR score in the CAO/ARO/AIO-04 randomized 
phase 3 trial. In that trial, the addition of oxaliplatin to 5-fluorouracil (5FU)-based 
preoperative CRT resulted in a significant improvement of the primary endpoint, DFS, 
compared to the standard arm [9, 10]. The aims of the present work were (a) to examine the 
prognostic role of the NAR score, and (b) to assess whether the NAR score constituted an 
individual-level surrogate for DFS according to the Prentice criteria (PC) that had been used 
to confirm that the treatment effect on the surrogate endpoint reflects the treatment effect on 
the clinical endpoint [11].  
 
PATIENTS AND METHODS 
Study design and participants 
The CAO/ARO/AIO-04 trial (ClinicalTrials.gov, number NCT00349076) was a multicenter, 
open-label, two arm randomized phase 3 study. The design, treatment plan and clinical 
outcome have been described before [9, 10]. The trial received approval by the ethics 
committee of the University of Erlangen, Germany. A +description of the design, 
pretreatment and pathologic examination, and follow-up is shown in Supplementary 
Methods; Supplementary Figure 1 illustrates the treatment plan. The full trial protocol is 
provided as Supplementary Material. 
 
Neoadjuvant rectal score 
The neoadjuvant rectal score (NAR) incorporates cT to account for tumor downstaging, and 
ypT and ypN that are influenced directly by preoperative treatment [8]. The NAR formula is 
as follows: NAR = [5 pN-3(cT-pT)+12]2 / 9.61, where cT in 1, 2, 3, 4, pT in 0, 1, 2, 3, 4 
and pN in 0, 1, 2. NAR consists of 24 distinct scores that range from 0 to 100. For ypT-
category and ypN-category, a relative weight of 3 and 5 was suggested to reflect the impact 
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of these variables, based on the nomogram of Valentini [7]. The constant 12 is included to 
maintain all scores inside the brackets as positive. The scaling factor 9.61 was introduced to 
ensure that the final scores range from 0 to 100.  
 
Statistical analysis 
The statistical analyses are described in detail in Supplementary Methods.  
 
RESULTS 
Patient characteristics and association of NAR with clinicopathologic factors 
Between July 2006 and February 2010, 1265 patients were recruited in the trial (CONSORT, 
Supplementary Figure 2). A total of 607 patients were actually treated with fluorouracil 
plus oxaliplatin-based preoperative CRT (5-FU/OX-CRT), and 625 patients actually received 
fluorouracil alone during CRT (5-FU-CRT). The NAR score was available in a total of 1191 
patients and Table 1 shows the results after both treatments. 5-FU/OX-CRT led to a 
statistically significant shift towards lower NAR scores as compared with 5-FU-CRT 
(P=0.034). The sample tertiles in the CAO/ARO/AIO-04 study population were similar to the 
NAR cut-offs of 8 and 16, as reported in the NSABP R-07 trial (Supplementary Table 1). 
Regarding pretreatment clinicopathologic characteristics (Supplementary Table 2), the 
proportion of patients with higher NAR scores was significantly increased in patients with 
age ≤ median, cN+, and less differentiated tumors. Also, NAR was significantly associated 
with several pathologic factors after preoperative CRT and surgery, including completeness 
of surgical resection, ypT-category, ypN-category, pathologic UICC-stage, circumferential 
resection margin involvement (CRM+) and a longer median interval between completion of 
preoperative CRT and surgery (Supplementary Table 3). The latter reflects the shifting 
towards lower ypT-categories and is in accordance to previous studies showing that longer 
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waiting periods between CRT completion and surgery led to increased tumor regression [12, 
13]. 
 
The prognostic role of NAR for clinical outcomes 
The median follow-up was 50 months (interquartile range=38-61 months). (Table 2). In 
univariate analysis, (Table 2; Figure 1) lower NAR score was significantly associated with 
better 3-year cumulative incidence of DFS, local recurrence, distant metastasis and OS (all 
P<0.001). We examined the prognostic significance of treatment arms and the 
clinicopathologic parameters in univariate analysis (Table 2). A significantly improved DFS 
(P=0.034) and local control (P=0.020) were observed following addition of oxaliplatin to 5-
FU-based CRT. Patients with complete surgical resection had significantly better DFS 
(P=0.014) and OS (P<0.001), whereas pathologic stage correlated with all four clinical 
endpoints (P<0.001 in each case). Circumferential resection margin showed statistical 
significance for DFS (P<0.001), cumulative incidence of distant metastasis (P<0.001), local 
recurrence (P<.001) and OS (P= .036). Older patients had significantly worse OS (P=0.001).  
We next conducted a multivariable analysis for all four clinical endpoints (Table 3). Due to 
multicollinearity that could lead to statistical bias, NAR and pathologic UICC stage could not 
be tested within the same model. Also, we excluded CRM as several cases were either 
missing or unknown. Low vs high NAR score constituted an independent prognostic factor 
for DFS (P<0.001), the cumulative incidence of local recurrence (P=0.002), the cumulative 
incidence of distant metastases (P< 0.001) and OS (P<0.001). Similar significant findings 
were observed for low vs intermediate NAR score with regard to all clinical endpoints with 
the exception of local recurrence (P=0.068) in multivariable analysis. Complete resection 
(R0) predicted for better DFS (P <0.001), cumulative incidence of distant metastases 
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(P=0.005) and OS (P<0.001). The experimental treatment arm was associated with better 
local control (P=0.021) (Table 3).  
 
NAR as a surrogate marker for DFS 
We evaluated the surrogacy of NAR score for DFS at an individual-patient level based on the 
four Prentice criteria [11]: PC 1 (significant treatment effect on DFS, P=0.034; Table 2), PC 
2 (significant impact of treatment arm on NAR, P=0.034, Table 1), and PC 3 (significant 
association between NAR score and DFS, P<0.001; Table 2) were fulfilled. PC 4 necessitates 
that the significant effect of the treatment arms on the primary endpoint DFS disappears once 
the surrogate is accounted for. The assessment for PC 4 was based on a Cox model for DFS 
with treatment arm and NAR included. The previously significant treatment effect on DFS (P 
= 0.034) as shown in Table 2 has now vanished from this model (HR 0.880, 95% CI 0.693-
1.116, P = 0.292), while the significant impact of NAR score (low vs. high) on DFS was 
retained (HR = 3.855; 95% CI 1.879-7.909; P < 0.001). Therefore, the treatment effect on 
DFS was captured by the NAR score, satisfying PC4. Additional sensitivity analyses were 
conducted to demonstrate the surrogacy of NAR for DFS based on PC 4 (Supplementary 
Methods and Results; Supplementary Figure 3) [14].  
 
DISCUSSION  
The NAR score has been proposed by the NRG Oncology as a primary endpoint to assess 
preoperative treatment efficacy in clinical trials in rectal cancer [8, 15]. The NAR score was 
prognostic for OS in a retrospective series [16] and the NSABP-R04 phase 3 trial dataset for 
the entire study cohort but analysis according to treatment arms was not performed [8]. The 
basic hypothesis is that changes in mean NAR scores between neoadjuvant treatment 
interventions should translate to changes in DFS or OS. The NAR score retained an 
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independent prognostic value for the primary endpoint, DFS, in multivariable analysis in the 
CAO/ARO/AIO-04 randomized phase 3 trial.  
Appropriate surrogate endpoints in trials depend on the clinical context, and require careful 
interpretation [17]. Surrogate endpoints in rectal cancer are lacking as their statistical 
validation poses major challenges, including confirmation in large trial datasets. In our study, 
the four PC [11] regarding the individual-level surrogacy of NAR for DFS were met. Several 
trials have used the PC in the recent years for assessment of potential surrogates [17-21]. It 
should be noted that the PC 4 is characterized by inherent difficulties in its interpretation that 
constitutes a methodological limitation in establishing surrogacy, and alternative methods 
have been proposed by Buyse and colleagues [6, 22, 23]. Also, assessment of NAR effects 
based on meta-analysis of large randomized trials is a prerequisite for the validation of its 
surrogacy at both the individual and trial levels [6], extending beyond the PC. Nevertheless, 
our large phase 3 trial in rectal cancer confirms the individual-level surrogacy of NAR score 
for DFS and corroborates its use as primary endpoint in (early) clinical trials, such as the 
NRG-GI002 using radiosensitizers  [24], to speed up evaluation of efficacy and access of new 
treatments. 
Other alternative early surrogate endpoints have been proposed, such as downsizing, 
downstaging, sterilizing lymph nodes, pathologic complete response (pCR), TRG, 
circumferential resection margin (CRM) involvement, R0 or sphincter sparing resections [25-
27]. The strength of the NAR score is the incorporation of both pre- and post-CRT variables 
to reflect initial tumor extent and tumor response. Weighing these variables based on their 
relative importance results in 24 possible discrete scores rather than in a dichotomized 
endpoint, as in the case of downstaging, pCR, CRM, R0. A shift of the pseudo-continuous 
NAR scores induced by different neoadjuvant interventions likely reflects treatment effects 
more accurately compared with binary endpoints.  
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Tumor regression grading has also been proposed to stratify tumor response to CRT and 
predict prognosis [3, 28, 29] but histopathologic standardization is lacking [30]. Pathologic 
complete response (pCR) correlates with survival after neoadjuvant treatment in breast cancer 
and the FDA allowed its use as surrogate endpoint for accelerated approval process [31, 32]. 
However, in rectal cancer, the role of pCR remains controversial and depends on several 
factors, such as the dose and the schedule of radiotherapy, combination with chemotherapy, 
and the time between treatment and surgery [26, 33, 34].  Yothers et al. showed that the NAR 
score had greater predictive ability than pCR for OS [35]. Finally, parameters such as the 
quality of total mesorectal excision can affect clinical outcome that could impact NAR and, 
hence, variability in quality assurance among trials should be considered when assessing the 
surrogacy of NAR for OS or DFS.  
We would like to acknowledge the limitations of our work. First, assessment of the 
prognostic value and surrogacy of NAR score was done post-hoc. Second, magnetic 
resonance imaging was not mandatory for baseline staging that could have affected the NAR 
score, considering the uncertainty of ultrasound when assessing cT- and cN-category. Third, 
central pathologic review was not conducted. Fourth, confirmation of PC 4 is discussed 
controversially due to the abovementioned inherent methodological limitations in 
establishing surrogacy, and alternative methods have been proposed [6, 14, 36] that should be 
taken into account. Fifth, analyses were done on the individual-level only. Sixth, the NAR 
score was developed based on Valentini nomogram for OS, whereas in the present work we 
assessed the surrogacy of NAR for DFS as the latter constituted the primary clinical endpoint.  
Altogether, our results corroborate the NRG Oncology strategy to use the NAR score as the 
primary endpoint in early phase rectal cancer trials including induction chemotherapy and 
molecular therapies. The NAR score constitutes an easily usable endpoint that can predict 
treatment effects and help oncologists to speed up response-adapted individualized 
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therapeutic decisions in the era of personalized medicine. These data pave the path for further 
validation of the NAR score in large phase 3 trial datasets to confirm trial-level surrogacy. 
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FIGURE LEGEND 
Figure 1. Prognostic significance of NAR score after preoperative chemoradiotherapy 
and TME surgery in rectal carcinoma. Prognostic significance of NAR for (A) disease-free 
survival; (B) cumulative incidence of local recurrence; (C) cumulative incidence of distant 
metastases; and (D) overall survival. Please note the different numbers at risk shown below 
each graph, according to the different clinical endpoint definition and available follow-up. 
Statistical significance was examined using the log-rank test, stratified by treatment arm and 
the statistical test was two-sided. In univariate analysis, the cumulative incidence of 
locoregional and distant recurrences was analyzed with death as competing risk, whereas all  
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Table 1. NAR score in patients treated with preoperative 5-FU based CRT +/- oxaliplatin and surgery  
NAR score 
Preoperative CRT 
with 5-FU 
as received  
n=625 
Preoperative  
CRT 
with 5-FU/Ox 
as received  
n=607 
Total 
n=1232 
P-value 
Low 116 (18.6%) 143 (23.6%) 259 0.034* 
Intermediate 305 (48.8%) 273 (45%) 578  
High 188 (30.1%) 166 (27.3%) 354  
Missing 10 (1.6%) 9 (1.5%) 19  
No surgery           6 (1%) 16 (2.6%) 22  
Abbreviations: NAR, neoadjuvant rectal; 5-FU, 5-fluorouracil; CRT, chemoradiotherapy; Ox, oxaliplatin; *p-value 
was calculated based on continuous NAR scores.  
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Table 2. Impact of different clinical and pathologic factors on clinical endpoints after preoperative 5-FU+/- Oxaliplatin CRT and surgery 
Clinical/Pathologic 
factors 
3-year DFS† 
(% [95% CI])  
P-
value  
3-year Cumulative 
incidence of local 
recurrence after 
R0/1†  
(% [95% CI]) 
P-value 
3-year Cumulative 
incidence of distant 
metastasis†  
(% [95% CI]) 
P-value  
3-year OS†  
(% [95% CI]) 
P-value 
All patients eligible 73.6 (71-76.1) 
 
3.2 (2.1-4.2) 
 
20.6 (18.2-22.9) 
 
88.4 (86.5-90.3) 
 
Treatment arm (as 
treated)         
5-FU-CRT 71.3 (67.6-74.9) 
 
3.7 (2.1-5.2) 
 
22.3 (18.9-25.6) 
 
88 (85.4-90.7) 
 
5-FU/OX-CRT 75.9 (72.3-79.5) 0.034 2.6 (1.2-3.9) 0.023 18.7 (15.5-22) 0.064 88.8 (86.1-91.4) 0.670 
 
Age         
Age <= median 73 (69.4-76.5) 
 
3.4 (1.8-4.9) 
 
22.6 (19.2-26) 
 
90.7 (88.2-93.1) 
 
Age > median 74.2 (70.5-77.8) 0.334 2.9 (1.5-4.3) 0.832 18.4 (15.2-21.6) 0.142 86 (83.1-88.9) 0.001 
 
Gender         
male 72.9 (69.9-76) 
 
3.7 (2.4-5.1) 
 
21.2 (18.4-24) 
 
88.6 (86.4-90.8) 
 
female 75.1 (70.4-79.7) 0.310 1.7 (0.3-3.1) 0.150 18.9 (14.7-23.1) 0.280 87.8 (84.2-91.4) 0.746 
 
Completeness of  
local resection 
        
R0 78.4 (75.8-80.9)  3.4 (2.3-4.5)  17 (14.7-19.3)  89.8 (87.9-91.6)  
R1 56.1 (33.0-79.2)  6.9 (0-17.6)  23.5 (3.8-43.2)  54.8 (33.8-75.7)  
R2* 0 (0%)  0 (0%)  8.3 (0-25.0)  43.1 (17.1-69)  
Rx 52.7 (25.0-80.5)  0  26.9 (1.8-52)  64.8 (39.6-90.1)  
Unknown/missing n.a 0.014 0 0.265 n.a. 0.534 n.a. <0.001 
 
Pathologic stage 
        
   ypT0N0 93.5 (89.8-97.2)  0 (0-0)  3.2 (0.6-5.9)  96.5 (93.7-99.2)  
   ypTisN0 100 (0-100)  0 (0-0)  0 (0-0)  100 (0-100)  
   I 89.2 (85.7-92.7)  0.5 (0-1.3)  7.6 (4.6-10.6)  95.5 (93.2-97.9)  
   IIA 74 (68.6-79.5)  3.3 (1.1-5.6)  19 (14.2-23.9)  87.9 (83.8-92)  
   IIB 64.1 (42.4-85.8)  8.5 (0-21.5)  26.3 (6.7-45.8)  91.3 (79.7-100)  
   IIIA 70.4 (60.7-80)  2.8 (0-6.2)  24.4 (15.3-33.5)  90.8 (84.7-96.9)  
   IIIB 66.9 (59-74.9)  3.5 (0.3-6.7)  29.5 (21.9-37.2)  86.5 (80.7-92.3)  
   IIIC 41.3 (30-52.7)  16.7 (7.8-25.6)  44.3 (32.8-55.8)  68.5 (57.6-79.5)  
   IV 0  3.8 (0-9.7)  0  48.2 (33.9-62.5)  
Unknown/Missing 57.1 (30.8-83.5) <0.001 20.3 (0-43.7) <0.001 2.6 (0.2-5) <0.001 61.3 (34.3-88.2) <0.001 
 
Circumferential 
resection margin 
        
pCR 93.5 (89.8-97.2) 
 
0 (0-0) 
 
3.2 (0.6-5.9) 
 
96.5 (93.7-99.2) 
 
<= 1mm 54.9 (39.2-70.6) 
 
19.3 (6.5-32) 
 
31.1 (17-45.2) 
 
69.5 (56.5-82.6) 
 
> 1mm - 2mm 63.5 (48.1-79) 
 
13.6 (2.9-24.4) 
 
24.5 (10.6-38.3) 
 
73.7 (59.5-87.9) 
 
> 2mm - Inf 75.5 (72.3-78.7) 
 
2.4 (1.3-3.6) 
 
19.8 (16.8-22.7) 
 
88.3 (85.9-90.7) 
 
Unknown/missing 80.1 (72.8-87.4) <0.001 4.8 (0.9-8.7) <0.001 13.5 (7.2-19.7) <0.001 87.6 (81.7-93.5) 0.036 
NAR score  
     
   
Low 91.7 (88.2-95.2) 
 
0 (0-0) 
 
5.6 (2.7-8.5) 
 
96.2 (93.8-98.7) 
 
Intermediate 81.8 (78.4-85.1) 
 
2.7 (1.3-4.1) 
 
13 (10.1-15.9) 
 
91 (88.6-93.5) 
 
High 58.1 (52.4-63.9) 
 
7.5 (4.5-10.4) 
 
34.5 (29-40) 
 
77.3 (72.6-82) 
 
Missing (surgery) 90.9 (73.9-100) <0.001 0 (0-0) <0.001 4.5 (0-13.5) <0.001 83.5 (60.4-100) <0.001 
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 The log-rank test was used to calculate statistical significance stratified by treatment arm. The cumulative incidence of locoregional and distant recurrences was 
assessed considering death as competing risk. The statistical test was two-sided.  
Abbreviations: DFS, disease-free survival; OS, overall survival; 5-FU, 5-fluorouracil; CRT, chemoradiotherapy; OX, oxaliplatin; pCR, pathologic complete 
response; NAR, neoadjuvant rectal; CI, confidence interval; n.a, not applicable;  
*For DFS and cumulative incidence of local recurrence, R2 an event.  
†With regard to post-surgical pathologic parameters, all clinical endpoints were calculated from date of surgery to prevent length bias. 
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DFS
†
 
Cumulative incidence of 
local recurrences after local  
R0/R1 resection
†
 
Cumulative incidence of 
distant metastases
†
 
     OS
†
 
N HR 95% CI P-value  HR 95% CI 
P-
value 
 HR 95% CI P-value  HR 95% CI P-value 
                
67 1 — —  1 — —  1 — —  1 — — 
57 0.842 (0.665-1.066)     0.154  0.496 (0.274-0.900) 0.021  0.859 (0.653-1.131) 0.280  0.904 (0.678-1.206) 0.493 
                
92 1 — —  1 — —  1 — —  1 — — 
32 2.650 (1.599-4.391) < 0.001  3.472 (1.359-8.867) 0.009  1.835 (0.964-3.495) 0.065  4.957 (3.293-7.460) <0.001 
                
255 1 — —  1 — —  1 — —  1 — — 
554 1.971 (1.303-2.980)   0.001  3.851 (0.903-16.419) 0.068  2.127 (1.256-3.602) 0.005  2.388 (1.349-4.225) 0.003 
315 4.670 (3.106-7.020) < 0.001  10.180 (2.418-42.851) 0.002  6.3 (3.775-10.515) <0.001  4.722 (2.694-8.726) <0.001 
Multivariable analyses were conducted using the Cox model for DFS and OS, and the Fine-Gray model for cumulative incidence of locoregional and distant recurrences. The statistical 
We first fitted Cox (or Fine-Gray) models with treatment arm and completeness of local resection. We then added NAR to this model, but kept the regression 
parameters for treatment arm and completeness of local resection fix (thus, the effect of NAR now describes the additional information contained in NAR).  Empty spaces appear as “—“ 
per definition of the endpoints. 
Abbreviations: DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; 5-FU, 5-fluorouracil; OX, oxaliplatin; CRT, chemoradiotherapy; NAR, 
resection were also included in the multivariable analysis for cumulative incidence of distant metastases and overall survival. 
surgical pathologic parameters, all clinical endpoints were calculated from date of surgery to prevent length bias. 
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